Related Experiment Videos
Hyperammonemia following allogeneic bone marrow transplantation.
N Tse1, S Cederbaum, J A Glaspy
1Department of Medicine, UCLA School of Medicine 90024-6596.
American Journal of Hematology
|October 1, 1991
Summary
Hyperammonemia, a serious chemotherapy complication, can occur after bone marrow transplants. Despite treatment, this metabolic issue can be fatal, necessitating new management strategies.
Area of Science:
- Oncology
- Nephrology
- Metabolic Medicine
Background:
- Intensive cytotoxic chemotherapy, particularly bone marrow transplantation (BMT), carries risks.
- Hyperammonemia is a rare but severe complication associated with such treatments.
Observation:
- A patient undergoing BMT for chronic myelogenous leukemia developed profound idiopathic hyperammonemia.
- The condition persisted despite aggressive interventions including hemodialysis and specific ammonia-lowering agents.
Findings:
- The patient's hyperammonemia was refractory to standard and experimental treatments.
- Ultimately, the patient succumbed to the metabolic derangements caused by hyperammonemia.
Implications:
- This case highlights the critical need for recognizing and managing hyperammonemia post-BMT.
- Further research into effective therapeutic strategies for chemotherapy-induced hyperammonemia is warranted.
- Developing guidelines for managing this complication in transplant recipients is essential.